47
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Hypertension-induced cognitive impairment: from pathophysiology to public health

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hypertension affects two-thirds of people aged >60 years and significantly increases the risk of both vascular cognitive impairment and Alzheimer’s disease. Hypertension compromises the structural and functional integrity of the cerebral microcirculation, promoting microvascular rarefaction, cerebromicrovascular endothelial dysfunction and neurovascular uncoupling, which impair cerebral blood supply. In addition, hypertension disrupts the blood–brain barrier, promoting neuroinflammation and exacerbation of amyloid pathologies. Ageing is characterized by multifaceted homeostatic dysfunction and impaired cellular stress resilience, which exacerbate the deleterious cerebromicrovascular effects of hypertension. Neuroradiological markers of hypertension-induced cerebral small vessel disease include white matter hyperintensities, lacunar infarcts and microhaemorrhages, all of which are associated with cognitive decline. Use of pharmaceutical and lifestyle interventions that reduce blood pressure, in combination with treatments that promote microvascular health, have the potential to prevent or delay the pathogenesis of vascular cognitive impairment and Alzheimer’s disease in patients with hypertension.

          Abstract

          Hypertension and ageing have deleterious effects on the cerebral microcirculation that can lead to cognitive dysfunction. This Review discusses cerebrovascular maladaptation to hypertension and microvascular contributions to hypertension-induced cognitive impairment in ageing, as well as the role of hypertension in the pathogenesis of Alzheimer’s disease.

          Key points

          • Hypertension is associated with ageing and significantly increases the risk of vascular cognitive impairment and Alzheimer’s disease.

          • In older individuals, hypertension leads to maladaptation of the cerebral circulation, resulting in dysregulation of cerebral blood flow, microvascular rarefaction, blood–brain barrier disruption, oxidative stress and impaired neurovascular coupling.

          • Hypertension causes pathological alterations in cerebral microvessels that damage microvascular structure, network architecture and function, and contribute to the genesis of cerebral microhaemorrhages, lacunar infarcts and white matter injury; these factors are associated with cognitive decline.

          • Potential mechanisms by which hypertension could exacerbate the progression of Alzheimer’s disease include increased oxidative microvascular damage, brain inflammation and blood–brain barrier disruption, as well as impaired glymphatic (also known as glial-lymphatic) clearance of amyloid-β.

          • Use of pharmaceutical and/or lifestyle interventions that reduce blood pressure in combination with treatments that promote microvascular health could potentially prevent or delay cognitive decline in patients with hypertension.

          Related collections

          Most cited references195

          • Record: found
          • Abstract: found
          • Article: not found

          The global epidemiology of hypertension

          Hypertension is the leading cause of cardiovascular disease and premature death worldwide. Owing to widespread use of antihypertensive medications, global mean blood pressure (BP) has remained constant or decreased slightly over the past four decades. By contrast, the prevalence of hypertension has increased, especially in low and middle-income countries (LMICs). Estimates suggest that in 2010, 31.1% of adults (1.39 billion) worldwide had hypertension. The prevalence of hypertension among adults was higher in LMICs (31.5%, 1.04 billion people) than in high-income countries (HICs; 28.5%, 349 million people). Variations in the levels of risk factors for hypertension, such as high sodium intake, low potassium intake, obesity, alcohol consumption, physical inactivity and unhealthy diet, may explain some of the regional heterogeneity in hypertension prevalence. Despite the increasing prevalence, the proportions of hypertension awareness, treatment and BP control are low, particularly in LMICs, and few comprehensive assessments of the economic impact of hypertension exist. Future studies are warranted to test implementation strategies for hypertension prevention and control, especially in low-income populations, and to accurately assess the prevalence and financial burden of hypertension worldwide.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries.

            Hypertension is the leading preventable cause of premature death worldwide. We examined global disparities of hypertension prevalence, awareness, treatment, and control in 2010 and compared secular changes from 2000 to 2010.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

              Hypertension is the most common condition seen in primary care and leads to myocardial infarction, stroke, renal failure, and death if not detected early and treated appropriately. Patients want to be assured that blood pressure (BP) treatment will reduce their disease burden, while clinicians want guidance on hypertension management using the best scientific evidence. This report takes a rigorous, evidence-based approach to recommend treatment thresholds, goals, and medications in the management of hypertension in adults. Evidence was drawn from randomized controlled trials, which represent the gold standard for determining efficacy and effectiveness. Evidence quality and recommendations were graded based on their effect on important outcomes. There is strong evidence to support treating hypertensive persons aged 60 years or older to a BP goal of less than 150/90 mm Hg and hypertensive persons 30 through 59 years of age to a diastolic goal of less than 90 mm Hg; however, there is insufficient evidence in hypertensive persons younger than 60 years for a systolic goal, or in those younger than 30 years for a diastolic goal, so the panel recommends a BP of less than 140/90 mm Hg for those groups based on expert opinion. The same thresholds and goals are recommended for hypertensive adults with diabetes or nondiabetic chronic kidney disease (CKD) as for the general hypertensive population younger than 60 years. There is moderate evidence to support initiating drug treatment with an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, calcium channel blocker, or thiazide-type diuretic in the nonblack hypertensive population, including those with diabetes. In the black hypertensive population, including those with diabetes, a calcium channel blocker or thiazide-type diuretic is recommended as initial therapy. There is moderate evidence to support initial or add-on antihypertensive therapy with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in persons with CKD to improve kidney outcomes. Although this guideline provides evidence-based recommendations for the management of high BP and should meet the clinical needs of most patients, these recommendations are not a substitute for clinical judgment, and decisions about care must carefully consider and incorporate the clinical characteristics and circumstances of each individual patient.
                Bookmark

                Author and article information

                Contributors
                anna-csiszar@ouhsc.edu
                Journal
                Nat Rev Nephrol
                Nat Rev Nephrol
                Nature Reviews. Nephrology
                Nature Publishing Group UK (London )
                1759-5061
                1759-507X
                14 June 2021
                : 1-16
                Affiliations
                [1 ]GRID grid.266902.9, ISNI 0000 0001 2179 3618, Vascular Cognitive Impairment and Neurodegeneration Program, Center for Geroscience and Healthy Brain Aging, Department of Biochemistry and Molecular Biology, , University of Oklahoma Health Sciences Center, ; Oklahoma City, OK USA
                [2 ]GRID grid.11804.3c, ISNI 0000 0001 0942 9821, International Training Program in Geroscience, Doctoral School of Basic and Translational Medicine/Department of Public Health, , Semmelweis University, ; Budapest, Hungary
                [3 ]GRID grid.266902.9, ISNI 0000 0001 2179 3618, Department of Health Promotion Sciences, College of Public Health, , University of Oklahoma Health Sciences Center, ; Oklahoma City, OK USA
                [4 ]GRID grid.9679.1, ISNI 0000 0001 0663 9479, Department of Neurosurgery, Medical School, , University of Pecs, ; Pecs, Hungary
                [5 ]GRID grid.266902.9, ISNI 0000 0001 2179 3618, Department of Neurology, , University of Oklahoma Health Sciences Center, ; Oklahoma City, OK USA
                [6 ]GRID grid.413864.c, ISNI 0000 0004 0420 2582, Veterans Affairs Medical Center, ; Oklahoma City, OK USA
                [7 ]GRID grid.16753.36, ISNI 0000 0001 2299 3507, Department of Neurology, Division of Stroke and Neurocritical Care, , Northwestern University Feinberg School of Medicine, ; Chicago, IL USA
                [8 ]GRID grid.11804.3c, ISNI 0000 0001 0942 9821, Heart and Vascular Center, , Semmelweis University, ; Budapest, Hungary
                [9 ]GRID grid.11804.3c, ISNI 0000 0001 0942 9821, International Training Program in Geroscience, Doctoral School of Basic and Translational Medicine/Institute of Clinical Experimental Research, , Semmelweis University, ; Budapest, Hungary
                Author information
                http://orcid.org/0000-0002-7749-2061
                http://orcid.org/0000-0002-6127-0739
                Article
                430
                10.1038/s41581-021-00430-6
                8202227
                34127835
                b28208e9-b958-4278-8296-7b016b097858
                © Springer Nature Limited 2021

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 21 April 2021
                Categories
                Review Article

                hypertension,neurological disorders,risk factors
                hypertension, neurological disorders, risk factors

                Comments

                Comment on this article

                scite_

                Similar content66

                Cited by126

                Most referenced authors3,005